The Cardiorenal Syndrome

Claudio Ronco, Chang-Yin Chionh, Mikko Haapio, Nagesh Anavekar, Andrew A House, Rinaldo Bellomo

Research output: Contribution to journalArticleResearchpeer-review

66 Citations (Scopus)

Abstract

The term cardiorenal syndrome (CRS) has increasingly been used in recent years without a constant meaning and a well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of the heart-kidney interactions, the classification of the CRS today includes 5 subtypes whose etymology reflects the primary and secondary pathology, the time frame and simultaneous cardiac and renal codysfunction secondary to systemic disease. The CRS can generally be defined as a pathophysiological disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ. Type I CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type II CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type III CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type IV CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events. Type V CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. Biomarkers can help to characterize the subtypes of the CRS and to indicate treatment initiation and effectiveness. The identification of patients and the pathophysiological mechanisms underlying each syndrome subtype will help to understand clinical derangements, to make the rationale for management strategies and to design future clinical trials with accurate selection and stratification of the studied population.
Original languageEnglish
Pages (from-to)114 - 126
Number of pages13
JournalBlood Purification
Volume27
Issue number1
DOIs
Publication statusPublished - 2009
Externally publishedYes

Cite this

Ronco, C., Chionh, C-Y., Haapio, M., Anavekar, N., House, A. A., & Bellomo, R. (2009). The Cardiorenal Syndrome. Blood Purification, 27(1), 114 - 126. https://doi.org/10.1159/000167018
Ronco, Claudio ; Chionh, Chang-Yin ; Haapio, Mikko ; Anavekar, Nagesh ; House, Andrew A ; Bellomo, Rinaldo. / The Cardiorenal Syndrome. In: Blood Purification. 2009 ; Vol. 27, No. 1. pp. 114 - 126.
@article{637e02c5c25d405aa242c02f72039b49,
title = "The Cardiorenal Syndrome",
abstract = "The term cardiorenal syndrome (CRS) has increasingly been used in recent years without a constant meaning and a well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of the heart-kidney interactions, the classification of the CRS today includes 5 subtypes whose etymology reflects the primary and secondary pathology, the time frame and simultaneous cardiac and renal codysfunction secondary to systemic disease. The CRS can generally be defined as a pathophysiological disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ. Type I CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type II CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type III CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type IV CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events. Type V CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. Biomarkers can help to characterize the subtypes of the CRS and to indicate treatment initiation and effectiveness. The identification of patients and the pathophysiological mechanisms underlying each syndrome subtype will help to understand clinical derangements, to make the rationale for management strategies and to design future clinical trials with accurate selection and stratification of the studied population.",
author = "Claudio Ronco and Chang-Yin Chionh and Mikko Haapio and Nagesh Anavekar and House, {Andrew A} and Rinaldo Bellomo",
year = "2009",
doi = "10.1159/000167018",
language = "English",
volume = "27",
pages = "114 -- 126",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "Karger",
number = "1",

}

Ronco, C, Chionh, C-Y, Haapio, M, Anavekar, N, House, AA & Bellomo, R 2009, 'The Cardiorenal Syndrome', Blood Purification, vol. 27, no. 1, pp. 114 - 126. https://doi.org/10.1159/000167018

The Cardiorenal Syndrome. / Ronco, Claudio; Chionh, Chang-Yin; Haapio, Mikko; Anavekar, Nagesh; House, Andrew A; Bellomo, Rinaldo.

In: Blood Purification, Vol. 27, No. 1, 2009, p. 114 - 126.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The Cardiorenal Syndrome

AU - Ronco, Claudio

AU - Chionh, Chang-Yin

AU - Haapio, Mikko

AU - Anavekar, Nagesh

AU - House, Andrew A

AU - Bellomo, Rinaldo

PY - 2009

Y1 - 2009

N2 - The term cardiorenal syndrome (CRS) has increasingly been used in recent years without a constant meaning and a well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of the heart-kidney interactions, the classification of the CRS today includes 5 subtypes whose etymology reflects the primary and secondary pathology, the time frame and simultaneous cardiac and renal codysfunction secondary to systemic disease. The CRS can generally be defined as a pathophysiological disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ. Type I CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type II CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type III CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type IV CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events. Type V CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. Biomarkers can help to characterize the subtypes of the CRS and to indicate treatment initiation and effectiveness. The identification of patients and the pathophysiological mechanisms underlying each syndrome subtype will help to understand clinical derangements, to make the rationale for management strategies and to design future clinical trials with accurate selection and stratification of the studied population.

AB - The term cardiorenal syndrome (CRS) has increasingly been used in recent years without a constant meaning and a well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of the heart-kidney interactions, the classification of the CRS today includes 5 subtypes whose etymology reflects the primary and secondary pathology, the time frame and simultaneous cardiac and renal codysfunction secondary to systemic disease. The CRS can generally be defined as a pathophysiological disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ. Type I CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type II CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type III CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type IV CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events. Type V CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. Biomarkers can help to characterize the subtypes of the CRS and to indicate treatment initiation and effectiveness. The identification of patients and the pathophysiological mechanisms underlying each syndrome subtype will help to understand clinical derangements, to make the rationale for management strategies and to design future clinical trials with accurate selection and stratification of the studied population.

UR - http://www.karger.com/Article/FullText/167018

U2 - 10.1159/000167018

DO - 10.1159/000167018

M3 - Article

VL - 27

SP - 114

EP - 126

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 1

ER -

Ronco C, Chionh C-Y, Haapio M, Anavekar N, House AA, Bellomo R. The Cardiorenal Syndrome. Blood Purification. 2009;27(1):114 - 126. https://doi.org/10.1159/000167018